BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
During activation, T cells express receptors for receiving positive and negative costimulatory signals. Here we identify the B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BTLA inhibits T/B cell activation and the secretion of cytokines11”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“anti-BTLA crosslinking may also cause the phosphorylation of the Src-homology domain 2 (SH2)-containing proteins tyrosine phosphatase-1 (SHP-1) and SHP-2 to activate suppression signaling”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“Additionally, the western blotting demonstrated that crosslinked BTLA promotes the phosphorylation of SHP-1/2, consistent with findings from previous studies11,42, and also activates the PI3K-Akt-GSK-3β pathway in purified CD4+ T cells.”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“BTLA is the essential co‐signaling immune checkpoint protein with bidirectional functions [331].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [331]
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
Self-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“, and Y282 is similar to the immunoreceptor tyrosine-based switch motif (ITSM) in PD-1 (ref”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Research works printed but not linked: 2
- Chambers, C.A. et al. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur. J. Immunol. 28, 3137–3143 (1998). · doi:10.1002/(sici)1521-4141(199810)28:10<3137::aid-immu3137>3.0.co;2-x
- Bachmann, M.F. et al. Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. Eur. J. Immunol. 31, 450–458 (2001). · DOI · Paper page
Cited by
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
“BTLA was first identified as an inhibitory receptor on T cells on the basis of the enhanced T cell responses that were observed in Btla -knockout mic”
BackgroundGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
“The repertoire of negative regulators expressed on T lymphocytes has increased in scope and complexity with the recent delineation of B- and T-lymphocyte attenuator (68) and a further as-yet-unidentified molecule bound by B7-H3 (62).”
BackgroundImmunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript In this regard, Watanabe and colleagues identified a third inhibitory receptor on T-cells: “the B- and T-lymphocyte attenuator (BTLA)” with similarities to CTLA-4 and PD-1 (94).”
BackgroundInfluentialInhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
“B- and T-lymphocyte attenuator (BTLA) was initially proposed to be the receptor for B7-H4 (Ref”
BackgroundImmune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
“BTLA contains ITIM and ITSM motifs as well as a Grb2 recognition motif in its cytoplasmic domain.(116) Both tyrosine residues in ITIM and ITSM can be phosphorylated and recruit SHP1/SHP2 to inhibit T cell function after ligation(116,117,125) (Fig.”
BackgroundPD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
“BTLA was recently identified as an immunoglobulin-superfamily member with limited homology to CTLA4 (Ref”
BackgroundVaddepally, R. K., Kharel, P., Pandey, R., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,196
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778
“B- and T-lymphocyte attenuator (BTLA), the most recently described member of the CD28 family (22), shares many features with PD-1 and may also be considered a CD28 family outlier.”
BackgroundBlank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
“In addition, the recently described inhibitory receptor BTLA that has functional similarities to PD-1 appears to recognize the B7 family member B7x (39, 40) that also could be expressed by tumor cells.”
BackgroundThe PD-1–PD-L pathway in immunological tolerance
Okazaki, T., & Honjo, T. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.02.001 · Cited by 721
Mechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E., & Pardoll, D. M. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 688
“Murphy and colleagues, have recently described a new member of the coinhibitor group of molecules, which they coined BTLA (B and T lymphocyte attenuator) (Watanabe et al., 2003).”
BackgroundFares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 653
Self-citationBlank, C., Gajewski, T. F., & Mackensen, A. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0593-x · Cited by 637
“The fact that PD-L1/PD-1 engagement can attenuate ICOS-positive costimulatory signals [5], that its negative signaling however can be negated by CD28 ligation or IL-2 [12], and the identification of a further negative regulatory receptor, BTLA [11, 75], indicates that the overall result from negative and positive cost…”
BackgroundSedy, J. R., Gavrieli, M., Potter, K. G., Hurchla, M. A., Lindsley, R. C., Hildner, K., Scheu, S., Pfeffer, K., Ware, C. F., Murphy, T. L., et al. (2005) · Nature Immunology · doi:10.1038/ni1144 · Cited by 632
“dtd" [ ]> The lymphoid-specific cell surface receptor B and T lymphocyte attenuator (BTLA) inhibits lymphocytes during immune response”
Self-citationCheckpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570
Self-citationThe pharmacology of second-generation chimeric antigen receptors
van der Stegen, S. J. C., Hamieh, M., & Sadelain, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4597 · Cited by 555
The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., et al. (2003) · Nature Immunology · doi:10.1038/ni967 · Cited by 576
A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION
Teft, W. A., Kirchhof, M. G., & Madrenas, J. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090535 · Cited by 518
Cardiovascular toxicities associated with immune checkpoint inhibitors
Hu, J.-R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., Lyon, A. R., Padera, R. F., Johnson, D. B., & Moslehi, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz026 · Cited by 508
Sanderson, K., Scotland, R., Lee, P., Liu, D., Groshen, S., Snively, J., Sian, S., Nichol, G., Davis, T., Keler, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 434
B7x: A widely expressed B7 family member that inhibits T cell activation
Zang, X., Loke, P., Kim, J., Murphy, K., Waitz, R., & Allison, J. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1434299100 · Cited by 405
Self-citationSHP‐1 and SHP‐2 in T cells: two phosphatases functioning at many levels
Lorenz, U. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00760.x · Cited by 372
“BTLA engagement has an inhibitory effect on IL-2 production (146).”
BackgroundNegative signaling by inhibitory receptors: the NK cell paradigm
Long, E. O. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00660.x · Cited by 370
The Molecular Signature of Tissue Resident Memory CD8 T Cells Isolated from the Brain
Wakim, L. M., Woodward-Davis, A., Liu, R., Hu, Y., Villadangos, J., Smyth, G., & Bevan, M. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201305 · Cited by 363
“Notably, two inhibitory receptors in the CD28:CTLA-4 family (22) (CTLA-4 and PD-1) are upregulated in brain CD103+ Trm cells compared with brain CD1032 and splenic CD1032 memory T cells.”
BackgroundInfluentialDendritic cell-mediated T cell polarization
de Jong, E. C., Smits, H. H., & Kapsenberg, M. L. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0167-1 · Cited by 367
“Furthermore, BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have an enhanced sensitivity to EAE, suggesting the involvement of possible regulatory T cells [129].”
BackgroundInfluentialAbbas, A. R., Baldwin, D., Ma, Y., Ouyang, W., Gurney, A., Martin, F., Fong, S., van Lookeren Campagne, M., Godowski, P., Williams, P. M., et al. (2005) · Genes & Immunity · doi:10.1038/sj.gene.6364173 · Cited by 377
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372
“BTLA deficient mice exhibit severe experimental autoimmune encephalomyelitis, prolonged airway allergic inflammation and higher rejection of minor mismatched allografts (8, 10, 11).”
Dendritic cell subsets and locations
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.07.004 · Cited by 349
Murine B7-H3 is a negative regulator of T cells
Prasad, D. V. R., Nguyen, T., Li, Z., Yang, Y., Duong, J., Wang, Y., & Dong, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2500 · Cited by 368
“10 T cell hybridoma cells, which express B7-H3 receptor after activation, are capable of producing IL-2 upon antiCD3 stimulation, and this IL-2 expression can be inhibited when a negative costimulator receptor was simultaneously engaged (24).”
BackgroundResultInfluentialPD-1 is a novel regulator of human B-cell activation
Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2013) · International Immunology · doi:10.1093/intimm/dxs098 · Cited by 365
Vstm3 is a member of the CD28 family and an important modulator of T‐cell function
Levin, S. D., Taft, D. W., Brandt, C. S., Bucher, C., Howard, E. D., Chadwick, E. M., Johnston, J., Hammond, A., Bontadelli, K., Ardourel, D., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201041136 · Cited by 356
CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator
Cai, G., Anumanthan, A., Brown, J. A., Greenfield, E. A., Zhu, B., & Freeman, G. J. (2008) · Nature Immunology · doi:10.1038/ni1554 · Cited by 345
“CD160 and BTLA might act coordinately in HVEM-mediated inhibition, whereby CD160 modulates the signaling complexes that translocate to lipid rafts and BTLA recruits tyrosine phosphatase”
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin, D. S., & Ribas, A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.006 · Cited by 346
Manipulating dendritic cell biology for the active immunotherapy of cancer
O'Neill, D. W., Adams, S., & Bhardwaj, N. (2004) · Blood · doi:10.1182/blood-2003-12-4392 · Cited by 339
The changing immune system in sepsis: Is individualized immuno-modulatory therapy the answer?
Boomer, J. S., Green, J. M., & Hotchkiss, R. S. (2014) · Virulence · doi:10.4161/viru.26516 · Cited by 317
Muenst, S., Soysal, S. D., Gao, F., Obermann, E. C., Oertli, D., & Gillanders, W. E. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2581-3 · Cited by 334
“Programmed death-1 (PD-1) is a member of the CD28/CTLA-4 family of costimulatory receptors, and, together with Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) [2] and B and T lymphocyte attenuator (BTLA) [3], conveys an inhibitory signal to the T cell.”
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation
Riley, J. L., & June, C. H. (2005) · Blood · doi:10.1182/blood-2004-04-1596 · Cited by 315
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
B7 family checkpoint regulators in immune regulation and disease
Ceeraz, S., Nowak, E. C., & Noelle, R. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.003 · Cited by 307
“54 Watanabe, N. et al. (2003) BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4, 670–679 55 Steinberg, M.W. et al. (2011) The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol. Rev. 244, 169–187 56 Compaan, D.M. et al. (2005) Atte…”
InfluentialB7-H3 and B7-H4 expression in non-small-cell lung cancer
Sun, Y., Wang, Y., Zhao, J., Gu, M., Giscombe, R., Lefvert, A. K., & Wang, X. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.05.012 · Cited by 316
Balancing co-stimulation and inhibition with BTLA and HVEM
Murphy, K. M., Nelson, C. A., & Šedý, J. R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1917 · Cited by 309
“BTLA was first identified as a transcript highly specific to T helper 1 (T H 1) cells”
BackgroundSelf-citationThe CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T‐cell activation
Cai, G., & Freeman, G. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00783.x · Cited by 301
“LIGHT and LTa are TNF superfamily members with a trimeric structure, while CD160 and BTLA are composed of a single Ig-like domain (8, 15).”
BackgroundResultInfluentialCo-stimulatory and Co-inhibitory Pathways in Autoimmunity
Zhang, Q., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.017 · Cited by 296
The immune system and cancer evasion strategies: therapeutic concepts
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304
Costimulatory and coinhibitory receptors in anti‐tumor immunity
Driessens, G., Kline, J., & Gajewski, T. F. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00771.x · Cited by 286
Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40070 · Cited by 295
An Enigmatic Tail of CD28 Signaling
Boomer, J. S., & Green, J. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002436 · Cited by 283
“CD28 and ICOS predominately enhance T-cell activation unlike CTLA-4, PD-1 and BTLA which are inhibitory (Rudd and Schneider 2003; Miller et al. 2009; Paterson et al. 2009; Rudd et al. 2009; Sharpe 2009).”
BackgroundInfluentialVSIG4, a B7 family-related protein, is a negative regulator of T cell activation
Vogt, L., Schmitz, N., Kurrer, M. O., Bauer, M., Hinton, H. I., Behnke, S., Gatto, D., Sebbel, P., Beerli, R. R., Sonderegger, I., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25673 · Cited by 272
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells
Boice, M., Salloum, D., Mourcin, F., Sanghvi, V., Amin, R., Oricchio, E., Jiang, M., Mottok, A., Denis-Lagache, N., Ciriello, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.032 · Cited by 257
“The inhibitory BTLA receptor has two ITIM domains that can interact with BCR signaling molecules (CD79, SHP1/2) (Gavrieli et al., 2003; Vendel et al., 2009; Watanabe et al., 2003).”
Advances in targeting cell surface signalling molecules for immune modulation
Yao, S., Zhu, Y., & Chen, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3877 · Cited by 267
Tewalt, E. F., Cohen, J. N., Rouhani, S. J., Guidi, C. J., Qiao, H., Fahl, S. P., Conaway, M. R., Bender, T. P., Tung, K. S., Vella, A. T., et al. (2012) · Blood · doi:10.1182/blood-2012-04-427013 · Cited by 270
Miyashita, M., Sasano, H., Tamaki, K., Hirakawa, H., Takahashi, Y., Nakagawa, S., Watanabe, G., Tada, H., Suzuki, A., Ohuchi, N., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0632-x · Cited by 253
“PD-1 is a member of the CD28/cytotoxic T-lymphocyte antigen 4 (CTLA-4) family of co-stimulatory receptors and is a negative regulator of T-cell lymphocytes [39, 40].”
BackgroundNg, S. Y.-M., Yoshida, T., Zhang, J., & Georgopoulos, K. (2009) · Immunity · doi:10.1016/j.immuni.2009.01.014 · Cited by 247
“…of secondary lymphoid organs which are absent in Ikaros-null mice (Alvarez et al., 2000; Gilfillan et al., 1993; Komori et al., 1993; Kuprash et al., 1999; Nakayama et al., 2005; Radtke et al., 2004; Sitnicka et al., 2003; Sitnicka et al., 2002; Tumanov et al., 2002; Watanabe et al., 2003).”
InfluentialThe signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation
Steinberg, M. W., Cheung, T. C., & Ware, C. F. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01064.x · Cited by 243
“In vitro studies have shown that HVEM-deficient as well as BTLA-deficient T cells are hyper-responsive after TCR stimulation with antiCD3 monoclonal antibodies (40, 47, 105).”
BackgroundResultInfluentialGonzalez, L. C., Loyet, K. M., Calemine-Fenaux, J., Chauhan, V., Wranik, B., Ouyang, W., & Eaton, D. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409071102 · Cited by 252
The new normal: immunomodulatory agents against sepsis immune suppression
Hutchins, N. A., Unsinger, J., Hotchkiss, R. S., & Ayala, A. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.01.002 · Cited by 239
Kloetzel, P. M. (2004) · Nature Immunology · doi:10.1038/ni1090 · Cited by 242
Cardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 246
“The T cell immunoglobulin and mucin-containing protein 3 (TIM-3), expressed on Treg cells, monocytes/ macrophages and APCs, regulate their functions.92 93 Anti-TIM-3 inhibits tumour growth.92 The lymphocyte-activated gene-3 (LAG-3, CD223) is expressed by CD4+ and CD8+ T cells, Treg and Tr1 cells.94–96 LAG-3 blockade s…”
BackgroundOX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Linch, S. N., McNamara, M. J., & Redmond, W. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00034 · Cited by 238
Tang, Y., Fang, W., Zhang, Y., Hong, S., Kang, S., Yan, Y., Chen, N., Zhan, J., He, X., Qin, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3694 · Cited by 243
“Programmed death 1 (PD-1) is a co-inhibitory receptor expressed on the membrane of activated T and B cells [6], which plays a crucial role in tumor immune escape [7, 8].”
BackgroundGeneration and maintenance of immunological memory
Gourley, T. S., Wherry, E. J., Masopust, D., & Ahmed, R. (2004) · Seminars in Immunology · doi:10.1016/j.smim.2004.08.013 · Cited by 231
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00649.x · Cited by 229
Self-citationWard, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 228
“…contribute to tumor-induced immunosuppression such as T cell Immunoglobulin and ITIM Domain (TIGIT), CD73, V-domain Ig suppressor of T cell activation (VISTA), and B and T lymphocyte attenuator have been identified (Chauvin et al., 2015; Jin et al., 2010; Wang et al., 2011; Watanabe et al., 2003).”
BackgroundTargeting co-stimulatory molecules in autoimmune disease
Edner, N. M., Carlesso, G., Rush, J. S., & Walker, L. S. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0081-9 · Cited by 228
Slow Down and Survive: Enigmatic Immunoregulation by BTLA and HVEM
Murphy, T. L., & Murphy, K. M. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101202 · Cited by 223
Self-citationOverall survival and PD‐L1 expression in metastasized malignant melanoma
Gadiot, J., Hooijkaas, A. I., Kaiser, A. D. M., van Tinteren, H., van Boven, H., & Blank, C. (2011) · Cancer · doi:10.1002/cncr.25747 · Cited by 221
“Recently, BTLA (B- and T-lymphocyte attenuator) and PD-1 (programmed cell death-1), both T-cell immuneinhibitory receptors of the CD28 family, have been added to the potential mediators of tumor immune escape.(13,14) Two ligands of PD-1, PDL-1 (PD-1, ligand 1; B7-H1) and PD-L2 (PD-1, ligand 2; B7-DC) have been shown t…”
BackgroundKumar, P., Bhattacharya, P., & Prabhakar, B. S. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.08.007 · Cited by 216
“B and T-Lymphocyte Associated (BTLA) is a unique co-inhibitory receptor of CD28 IgSF [64] which binds to TNFRSF member HVEM (TNFRSF14)[65].”
BackgroundHaanen, J. B. A. G., & Robert, C. (2015) · Progress in Tumor Research · doi:10.1159/000437178 · Cited by 208
Salceda, S., Tang, T., Kmet, M., Munteanu, A., Ghosh, M., Macina, R., Liu, W., Pilkington, G., & Papkoff, J. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.01.018 · Cited by 217
Zhang, Y., Wang, L., li, Y., Pan, Y., Hu, H., Li, H., Luo, X., Ye, T., sun, Y., chen, H., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s59959 · Cited by 213
“Programmed death 1 (PD-1) is a coinhibitory receptor induced on activated T and B cells,(2) and it plays a crucial role in tumor immune escape.(3,4) Two ligands of PD-1, PD-L1 (B7-H1) and PD-L2 (B7-DC), have been identified as negative immune regulators by engaging PD-1 receptor.”
BackgroundT follicular helper cells in germinal center B cell selection and lymphomagenesis
Mintz, M. A., & Cyster, J. G. (2020) · Immunological Reviews · doi:10.1111/imr.12860 · Cited by 204
Cheung, T. C., Humphreys, I. R., Potter, K. G., Norris, P. S., Shumway, H. M., Tran, B. R., Patterson, G., Jean-Jacques, R., Yoon, M., Spear, P. G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506172102 · Cited by 209
Self-citationThe Roles of the New Negative T Cell Costimulatory Pathways in Regulating Autoimmunity
Khoury, S. J., & Sayegh, M. H. (2004) · Immunity · doi:10.1016/s1074-7613(04)00116-5 · Cited by 209
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 199
“BTLA- HVEM engagement in T cells leads to tyrosine phosporylation on the conserved intracellular ITIM, inducing recruitment of the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2 resulting in diminished CD3-induced secretion of IL-2 and T cell proliferation [108, 111].”
BackgroundResultInfluentialThe role of programming in memory T-cell development
Masopust, D., Kaech, S. M., Wherry, E. J., & Ahmed, R. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.02.005 · Cited by 206
Han, P., Goularte, O. D., Rufner, K., Wilkinson, B., & Kaye, J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.5931 · Cited by 201
Pentcheva‐Hoang, T., Corse, E., & Allison, J. P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00763.x · Cited by 203
“BTLA is type I membrane glycoprotein of the IgSF that was first identified as an expressed sequence tag (EST) in Th1-polarized TCR transgenic T cells (29) and independently as an EST expressed after activation of double-positive thymocytes (223).”
BackgroundMethodInfluentialSelf-citationBeyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
Le Mercier, I., Lines, J. L., & Noelle, R. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00418 · Cited by 195
“BTLA-deficient mice also present increased susceptibility to EAE (129) and mice deficient in either BTLA or HVEM present heightened T cell and NKT cell responses to Con A and exhibit increased morbidity and mortality to Con A-mediated T cell-dependent autoimmune hepatitis (138, 139).”
BackgroundInfluentialCell Surface Signaling Molecules in the Control of Immune Responses: A Tide Model
Zhu, Y., Yao, S., & Chen, L. (2011) · Immunity · doi:10.1016/j.immuni.2011.04.008 · Cited by 196
Costimulatory pathways in transplantation: challenges and new developments
Li, X. C., Rothstein, D. M., & Sayegh, M. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00781.x · Cited by 197
“The inhibitory role of BTLA was confirmed in mice genetically deficient for BTLA, which exhibit amplified immune responses in vivo (175).”
BackgroundYogev, N., Frommer, F., Lukas, D., Kautz-Neu, K., Karram, K., Ielo, D., von Stebut, E., Probst, H.-C., van den Broek, M., Riethmacher, D., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.025 · Cited by 197
“, 2005; Waisman and Yogev, 2009) and BTLA is a negative costimulatory molecule (Han et al., 2004; Watanabe et al., 2003), we tested whether the expression of these molecules upon immunization would be affected by DC ablation.”
Baitsch, L., Legat, A., Barba, L., Fuertes Marraco, S. A., Rivals, J.-P., Baumgaertner, P., Christiansen-Jucht, C., Bouzourene, H., Rimoldi, D., Pircher, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030852 · Cited by 184
“downregulated in memory and effector cells [9,10].”
Unconventional ligand activation of herpesvirus entry mediator signals cell survival
Cheung, T. C., Steinberg, M. W., Oborne, L. M., Macauley, M. G., Fukuyama, S., Sanjo, H., D'Souza, C., Norris, P. S., Pfeffer, K., Murphy, K. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902115106 · Cited by 192
“On the other side, HVEM binding to BTLA induces phosphorylation of the immunotyrosine inhibitory motif and recruitment of the tyrosine phosphatases SHP1 and SHP2, which attenuate signaling initiated by tyrosine kinases involved in promoting cellular activation and growth (5, 11, 12).”
BackgroundMethodSelf-citationThe role of B7 family molecules in hematologic malignancy
Greaves, P., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2012-10-385591 · Cited by 187
Gavrieli, M., Watanabe, N., Loftin, S. K., Murphy, T. L., & Murphy, K. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.070 · Cited by 190
Self-citationWhat did we learn from CTLA‐4 insufficiency on the human immune system?
Mitsuiki, N., Schwab, C., & Grimbacher, B. (2019) · Immunological Reviews · doi:10.1111/imr.12721 · Cited by 177
Smith, P., Walsh, C. M., Mangan, N. E., Fallon, R. E., Sayers, J. R., McKenzie, A. N. J., & Fallon, P. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.1240 · Cited by 185
“This discrepancy may be due to the recent demonstrations of PD-1-independent activities for PD-L1/2 (48–50) and potential roles for additional T cell inhibitory receptors (51).”
BackgroundHurchla, M. A., Sedy, J. R., Gavrielli, M., Drake, C. G., Murphy, T. L., & Murphy, K. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3377 · Cited by 181
“BTLA / lymphocytes showed increased proliferation (15, 17), and BTLA / mice showed en-”
BackgroundMethodResultSelf-citationA comprehensive review of immune checkpoint inhibitors for cancer treatment
Arafat Hossain, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 178
Targets for immunotherapy of liver cancer
Greten, T. F., & Sangro, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.007 · Cited by 168
“BTLA is able to inhibit T cell proliferation and cytokine production upon binding to its ligand, herpesvirus entry mediator (HVEM), which can be expressed in HCC [14,15].”
Attenuating Lymphocyte Activity
Compaan, D. M., Gonzalez, L. C., Tom, I., Loyet, K. M., Eaton, D., & Hymowitz, S. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507629200 · Cited by 170
Takahashi, N., Matsumoto, K., Saito, H., Nanki, T., Miyasaka, N., Kobata, T., Azuma, M., Lee, S., Mizutani, S., & Morio, T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803256 · Cited by 173
“Induction of BTLA, another inhibitory receptor with similarities to CTLA-4 (5), was then estimated.”
BackgroundPotential targeting of B7‐H4 for the treatment of cancer
Podojil, J. R., & Miller, S. D. (2017) · Immunological Reviews · doi:10.1111/imr.12530 · Cited by 159
Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer
Hoeres, T., Smetak, M., Pretscher, D., & Wilhelm, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00800 · Cited by 154
“B- and T-lymphocyte attenuator was suggested to inhibit late phases of immune reactions and has structural and functional similarities to PD-1 and CTLA4 (204).”
BackgroundInfluentialIn vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses
Shin, T., Yoshimura, K., Shin, T., Crafton, E. B., Tsuchiya, H., Housseau, F., Koseki, H., Schulick, R. D., Chen, L., & Pardoll, D. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050072 · Cited by 154
“Mice were injected with 100 � g NP17-KLH (Biosearch Technologies, Inc.) with alum (Pierce Chemical Co.) on d 0 and 14. Mice sera were collected on d 28. The titers of isotype and subclass of anti-NP‐specific antibody were detected by ELISA using NP25-BSA (Biosearch Technologies, Inc.) for antibody capture and SBA Clon…”
Method
Metadata
- Authors
- Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., Murphy, T. L., Russell, J. H., Allison, J. P., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Boehringer Ingelheim (Germany) (DE)
- University of Perugia (IT)
- Washington University in St. Louis (US)
- Corresponding author
- Murphy, Kenneth M
- ORCID
- Venue
- Nature Immunology
- Published
- 2003-06-08
- Volume
- 4
- Issue
- 7
- Pages
- 670-679
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2118705059
- Cited by
- 883
- References
- 52
- Citations by year
- 2026: 26 · 2025: 30 · 2024: 38 · 2023: 38 · 2022: 38 · 2021: 59 · 2020: 56 · 2019: 49 · 2018: 35 · 2017: 29 · 2016: 31 · 2015: 36 · 2014: 34 · 2013: 41 · 2012: 37
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- BTLA, inhibitory receptors, T cell costimulation, CTLA-4, PD-1, SHP-1, SHP2, tyrosine phosphorylation, interleukin-2, T helper cell differentiation, B7 ligands, T cell proliferation, experimental autoimmune encephalomyelitis, antibody response
- MeSH terms
- Abatacept, Amino Acid Sequence, Animals, Antigens, Differentiation, Antigens, Surface, Encephalomyelitis, Autoimmune, Experimental, Interleukin-2, Lymphocyte Activation, Molecular Sequence Data, Phosphorylation, Proteins, Receptors, Immunologic, RNA, Messenger, T-Lymphocytes, Antigens, CD, Protein Tyrosine Phosphatases, B7-1 Antigen, Immunoconjugates, Intracellular Signaling Peptides and Proteins, Apoptosis Regulatory Proteins, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 6, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Protein Tyrosine Phosphatase, Non-Receptor Type 11, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.